Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vaxcyte Inc
(NQ:
PCVX
)
88.95
+2.99 (+3.48%)
Streaming Delayed Price
Updated: 2:38 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vaxcyte Inc
< Previous
1
2
3
4
5
Next >
1 Vanguard Index Fund May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst
November 20, 2024
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
November 17, 2024
10 worst performing large-cap stocks last week: MPWR, SMCI, MRNA, LDOS, MNDY, PCVX, BAH, ABBV, CACI, XPEV. Check if they're in your portfolio.
Via
Benzinga
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
November 12, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
November 05, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Peering Into Vaxcyte's Recent Short Interest
October 30, 2024
Via
Benzinga
Peering Into Vaxcyte's Recent Short Interest
August 27, 2024
Via
Benzinga
PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024
May 08, 2024
PCVX stock results show that Vaxcyte beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
September 11, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 06, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
September 04, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Recap: Vaxcyte Q4 Earnings
February 27, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
September 03, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 03, 2024
Via
Benzinga
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
September 03, 2024
Via
Benzinga
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
September 03, 2024
Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, showing strong immune responses and safety comparable to Pfizer's...
Via
Benzinga
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
September 03, 2024
The company is looking to take on Pfizer in the massive pneumococcal conjugate vaccine market.
Via
Investor's Business Daily
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
September 03, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
September 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
August 06, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Appoints John Furey to Board of Directors
July 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
April 10, 2024
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the...
Via
Benzinga
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
March 12, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
March 04, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 15, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
February 01, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.